carbidopa


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to carbidopa: Entacapone

car·bi·do·pa

 (kär′bĭ-dō′pə)
n.
A drug, C10H14N2O4, that increases the availability of L-dopa to the brain and is administered with L-dopa to treat Parkinson's disease.

[Alteration of carbo- + dopa.]
Translations

carbidopa

n carbidopa
Mentioned in ?
References in periodicals archive ?
researchers have recently discovered that a drug - carbidopa - used to treat Parkinson's disease significantly displayed
Duodopa is the brand name for a drug called Carbidopa Monohydrate/Levodopa.
L-dopa used to be used in Parkinson's but had to be mixed with carbidopa to control the nausea.
According to a company news release, Duopa provides patients with the same active ingredients as orally administered carbidopa and levodopa immediate release but is delivered in a suspension that goes directly into the small intestine via a tube.
Levodopa is almost always given in combination with carbidopa, which prevents levodopa from converting to dopamine before it reaches the brain.
Summary: TEHRAN (FNA)- An Iranian researcher presented an appropriate and quick method based on electrochemical methods by synthesizing carbon nanotube modified electrode to measure carbidopa drug in the treatment of Parkinson's disease.
Mumbai, April 24 -- Pharmaceutical and biotechnology major Wockhardt has launched an authorized generic version of four strengths (50mg, 75mg, 125mg and 200mg) of the triple-drug combination product containing Levodopa, Carbidopa and Entacapone, which are used in treatment of Parkinson's disease.
A randomized double-blinded trial followed 423 patients for 39 weeks to compare the combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone and levodopa/carbidopa (LCE) with levodopa/ carbidopa alone (LC).
One of the most common PD medications is a combination of levodopa and carbidopa (Sinemet).
Carbidopa often is added to the regimen to prevent levodopa from being converted to dopamine in the brain, thus allowing more of the levodopa to reach the brain (PDF, 2010c).
21 October 2009 - Finnish pharmaceutical company Orion Oyj (HEL: ORNBV) said today it withdrew the US application for extending the current indication of its drug Stalevo (levodopa, carbidopa and entacapone) to patients with early Parkinson's disease.
has initiated a Phase II trial of Droxidopa, a synthetic precursor of norepinephrine, both alone and in combination with carbidopa for the treatment of Fibromyalgia.